8-K: Mirum Pharmaceuticals Announces Positive Interim Results for Volixibat in PBC Trial, PSC Trial to Continue

Mirum Pharmaceuticals reported positive interim results from a Phase 2b trial of volixibat for primary biliary cholangitis (PBC), showing significant improvement in pruritus, and announced that a separate trial for primary sclerosing cholangitis (PSC) will continue.

Summary

• Mirum Pharmaceuticals announced interim results from two Phase 2b studies of volixibat, an oral ileal bile acid transporter inhibitor.
• The VANTAGE trial for PBC showed a statistically significant improvement in pruritus with a -3.82 point reduction and a placebo-adjusted difference of -2.32 points, as measured by the Adult ItchRO scale.
• 75% of patients on volixibat achieved a greater than 50% reduction in serum bile acids.
• There was also a significant improvement in fatigue at week 16 with volixibat compared to placebo.
• The most common adverse event was diarrhea, with 77% of patients experiencing it, mostly mild to moderate and transient.
• The VISTAS trial for PSC will continue with the selected volixibat dose of 20 mg twice daily, based on the recommendation of the independent data review committee.
• The sponsor and investigators are blinded to the interim results and analysis for the PSC trial.

Sentiment

Score: 8

Explanation: The document presents positive interim results from a Phase 2b trial, indicating potential for a new treatment option. The continuation of both trials is also a positive sign. However, the presence of adverse events and the inherent risks of drug development temper the overall sentiment.

Positives

• The VANTAGE trial demonstrated a statistically significant improvement in pruritus.
• A large percentage of patients experienced a significant reduction in serum bile acids.
• Volixibat showed a significant improvement in fatigue compared to placebo.
• The VISTAS trial for PSC will continue, indicating no major safety concerns and meeting predefined efficacy thresholds.

Negatives

• Diarrhea was a common adverse event, affecting 77% of patients, although mostly mild to moderate and transient.
• Four patients experienced serious adverse events, including one in the placebo arm.

Risks

• The forward-looking statements are subject to risks and uncertainties associated with pharmaceutical research and development.
• Actual results may differ from those reported due to various factors.
• The company is exposed to risks and uncertainties inherent in its business.

Future Outlook

The VANTAGE and VISTAS clinical trials are anticipated to continue, but actual results may differ due to various risks and uncertainties.

Management Comments

• The company announced interim results from two Phase 2b studies evaluating volixibat.
• The VANTAGE PBC clinical trial will continue with a volixibat dose of 20 mg twice daily.
• The VISTAS PSC clinical trial will continue with the selected volixibat dose of 20 mg twice daily.

Industry Context

This announcement is significant for the treatment of PBC and PSC, which are chronic liver diseases with limited treatment options. Positive results could position Mirum as a key player in this therapeutic area.

Comparison to Industry Standards

• The reported improvement in pruritus and reduction in serum bile acids are clinically meaningful endpoints in PBC trials, often compared to existing treatments like ursodeoxycholic acid (UDCA).
• The 75% of patients achieving a greater than 50% reduction in serum bile acids is a strong result, potentially exceeding outcomes seen with some current therapies.
• The continuation of the PSC trial is a positive sign, as this disease has very few effective treatments, and any positive data is closely watched by the medical community.

Stakeholder Impact

• Shareholders may react positively to the promising interim results.
• Patients with PBC and PSC may benefit from the potential new treatment option.
• The company's employees may be motivated by the positive progress in clinical trials.

Next Steps

• The VANTAGE PBC clinical trial will continue with a volixibat dose of 20 mg twice daily.
• The VISTAS PSC clinical trial will continue with the selected volixibat dose of 20 mg twice daily.

Key Dates

Keywords

volixibat, primary biliary cholangitis, primary sclerosing cholangitis, PBC, PSC, pruritus, bile acid transporter inhibitor, clinical trial, VANTAGE, VISTAS